The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy

The article by Wilson et al., published in the February 2021 issue, reported the prognostic value of circulating tumor DNA (ctDNA) sequencing in head and neck squamous cell carcinoma (HNSCC), noting TP53 as the most altered and concordant gene in ctDNA and tDNA. This Letter to the Editor further considers the role of TP53 alteration in the prognosis prediction of immunotherapy in HNSCC.

Automated summary

The study examines the prognostic value of circulating tumor DNA sequencing in head and neck squamous cell carcinoma, highlighting TP53 as a central gene of interest and its potential role in predicting immunotherapy outcomes in HNSCC.